---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-030110"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:20:35.937827+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmuCell appoints Olivier te Boekhorst as President and CEO effective Nov 1, 2025

## Summary
- Olivier te Boekhorst, former IDEXX Senior VP and Archimed Operating Partner, named CEO.
- Current CEO Michael Brigham to become Special Advisor for at least two months and remain on Board.
- Base salary of $450,000, annual bonus up to $400,000, $100,000 signing bonus.
- Received inducement stock option for 76,673 shares at $5.90; second grant for up to 85,000 shares.
- Options vest over three years; options granted Sep 16, 2025 have 10-year term.

## SEC filing metadata
- accession: 0001437749-25-030110
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02, 9.01, 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774925030110/0001437749-25-030110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774925030110/iccc20250827_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-030110
- JSON: https://secwatch.observer/filing/0001437749-25-030110.json
- Plain text: https://secwatch.observer/filing/0001437749-25-030110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.